drugset / Trial / NCT01504165
Pharmacokinetics in Subjects With Renal Impairment
Non-randomizedParallel-groupOpen-label
Summary
This is an open-label, non-randomized, parallel-group, mono-center, single intravenous dose, Phase I trial to investigate the Pharmacokinetic (PK) and safety of cilengitide in subjects with different grades of renal impairment as compared to subjects with normal renal function.
Timeline
- Start
- 2012-01
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cilengitide | Peptide | 1000 mg | Intravenous |
| Subject | cilengitide | Peptide | 2000 mg | Intravenous |